Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
74 hedge funds and large institutions have $485M invested in Orchard Therapeutics plc American Depositary Shares in 2020 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 19 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less funds holding
Funds holding: 81 → 74 (-7)
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
46% less capital invested
Capital invested by funds: $895M → $485M (-$410M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$45.8M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$18.7M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$11.1M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$5.51M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Element Capital Management
New York
|
-$13.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.8M |
| 3 |
JP Morgan Chase
New York
|
-$11.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.79M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.91M |
ORTX Hedge Fund Activity: Q1 2020 in Review
74 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q1 2020, worth a combined $485M — down 46% from $895M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ORTX and 13 opened new positions — a net loss of 6 holders — while 22 trimmed existing stakes and 26 added.
The largest buyer was RA Capital Management, adding an estimated $45.8M. The largest seller was Element Capital Management, exiting entirely with an estimated $13.4M sold.
- 74 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q1 2020, down from 81 in Q4 2019.
- Funds reported $485M of Orchard Therapeutics plc American Depositary Shares stock for Q1 2020, down 46% quarter-over-quarter.
- 13 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q1 2020 and 19 closed out, a net change of -6 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q1 2020 was RA Capital Management, an estimated $45.8M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q1 2020 was Element Capital Management, an estimated $13.4M sold.
Based on aggregated 13F filings for Q1 2020.